CD19/CD3, Blinatumomab Biosimilar (CD19, CD3E)

Größe

£550.00

SKU:: 591717
Reinheit:: Purified by Protein A/G affinity chromatography. ≥95%. Endotoxin: ≤1EU/mg (LAL)
Lagerbedingungen:: -20°C
Hersteller:: United States Biological
Host:: Mouse
Immunogen:: Recombinant protein corresponding to human CD19/CD3E, expressed in CHO cells.
Format:: Supplied as a liquid in PBS. No preservative added.
Weitere Details:: Blinatumomab is a BiTE-class (bi-specific T-cell engagers) constructed monoclonal antibody indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Blinatumomab is manufactured by Amgen Inc. and marketed under the brand Blincyto™. Blinatumomab was approved in December 2014 under the FDA’s accelerated approval program which allows approval of a drug to treat a serious or life-threatening disease based on clinical data showing the drug has an effect on a surrogate endpoint reasonably likely to predict clinical benefit to patients. Applications: Suitable for use in Functional Assays. Other applications not tested. Recommended Dilution: Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.